These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 5337985)

  • 1. Symposium on immunosuppressive drugs. Folate antagonists: some biochemical and pharmacological considerations.
    Bertino JR; Hillcoat BL; Johns DG
    Fed Proc; 1967; 26(3):893-7. PubMed ID: 5337985
    [No Abstract]   [Full Text] [Related]  

  • 2. A review of the actions and effects of immunosuppressive drugs.
    Sarles HE; Thomas FD; Remmers AR; Canales CO; Smith GH; Beathard GA
    Tex Rep Biol Med; 1969; 27(2):327-40. PubMed ID: 4900373
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunosuppressive agents.
    Gerebtzoff A; Lambert PH; Miescher PA
    Annu Rev Pharmacol; 1972; 12():287-316. PubMed ID: 4556943
    [No Abstract]   [Full Text] [Related]  

  • 4. [Immunodepressants (review of the literature)].
    Uteshev BS; Kovalev IE
    Farmakol Toksikol; 1967; 30(3):361-72. PubMed ID: 4876661
    [No Abstract]   [Full Text] [Related]  

  • 5. [Depression of immunity with chemical agents].
    Ado VA
    Patol Fiziol Eksp Ter; 1974; (5):82-7. PubMed ID: 4612470
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunosuppressive drugs.
    Makinodan T; Santos GW; Quinn RP
    Pharmacol Rev; 1970 Jun; 22(2):189-247. PubMed ID: 4914001
    [No Abstract]   [Full Text] [Related]  

  • 7. [Immunosuppressive agents].
    Sabbaga E
    Hospital (Rio J); 1966 Nov; 70(5):1199-206. PubMed ID: 5302166
    [No Abstract]   [Full Text] [Related]  

  • 8. Symposium on immunosuppressive drugs. Variable influences of antitumor drugs and progestational agents on immune responses in rodents.
    Haines RF; Johnson AG; Petering HG
    Fed Proc; 1967; 26(3):934-43. PubMed ID: 5337287
    [No Abstract]   [Full Text] [Related]  

  • 9. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
    Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G
    Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of folate antagonists.
    Johns DG; Valerino DM
    Ann N Y Acad Sci; 1971 Nov; 186():378-86. PubMed ID: 5289427
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of membrane-associated folate binding protein in the cytotoxicity of antifolates in KB, IGROV1, and L1210A cells.
    Schultz RM; Andis SL; Shackelford KA; Gates SB; Ratnam M; Mendelsohn LG; Shih C; Grindey GB
    Oncol Res; 1995; 7(2):97-102. PubMed ID: 7579732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms of cellular resistance to folate analogs.
    Grzelakowska-Sztabert B
    Prog Clin Biol Res; 1983; 132C():213-22. PubMed ID: 6634773
    [No Abstract]   [Full Text] [Related]  

  • 13. Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid.
    Alati T; Worzalla JF; Shih C; Bewley JR; Lewis S; Moran RG; Grindey GB
    Cancer Res; 1996 May; 56(10):2331-5. PubMed ID: 8625328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and pharmacologic properties of a new folate analog, 10-deaza-aminopterin, in mice.
    Sirotnak FM; DeGraw JI; Chello PL; Moccio DM; Dorick DM
    Cancer Treat Rep; 1982 Feb; 66(2):351-8. PubMed ID: 7055818
    [No Abstract]   [Full Text] [Related]  

  • 15. Folate antagonists.
    Bertino JR; Johns DG
    Annu Rev Med; 1967; 18():27-34. PubMed ID: 5337527
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells.
    Genestier L; Paillot R; Fournel S; Ferraro C; Miossec P; Revillard JP
    J Clin Invest; 1998 Jul; 102(2):322-8. PubMed ID: 9664073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new concept of immunosuppression in hypersensitivity reactions and in transplantation immunity.
    Nelson RA
    Surv Ophthalmol; 1966 Aug; 11(4):498-505. PubMed ID: 5919620
    [No Abstract]   [Full Text] [Related]  

  • 18. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration.
    Jansen G; Barr H; Kathmann I; Bunni MA; Priest DG; Noordhuis P; Peters GJ; Assaraf YG
    Mol Pharmacol; 1999 Apr; 55(4):761-9. PubMed ID: 10101035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of membrance transport in the pharmacologic action of antifolates.
    Sirotnak FM
    Cancer Treat Rep; 1981; 65 Suppl 1():19-27. PubMed ID: 7326662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.